June 21, 2021 -- Arrowhead Pharmaceuticals and Horizon Therapeutics are collaborating on ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic.
The drug could potentially treat people with uncontrolled gout as it targets the primary source of serum uric acid.
Arrowhead will handle the drug's preclinical stages of development and Horizon will receive a worldwide exclusive license. Horizon will be wholly responsible for clinical development and commercialization.
Horizon will pay Arrowhead $40 million upfront and Arrowhead is eligible to receive up to $660 million in potential development, regulatory, and commercial milestones. The firm is also eligible to receive royalties in the low- to mid-teens range on net product sales, according to a press release.
Copyright © 2021 scienceboard.net